Kathryn V Roberts1, Graeme P Maguire2, Alex Brown3, David N Atkinson4, Bo Remenyi5, Gavin Wheaton6, Marcus Ilton5, Jonathan Carapetis7. 1. Menzies School of Health Research, Darwin, NT kathryn.roberts@menzies.edu.au. 2. Baker IDI Heart and Diabetes Institute, Melbourne, VIC. 3. South Australian Health and Medical Research Institute, Adelaide, SA. 4. University of Western Australia, Broome, WA. 5. Royal Darwin Hospital, Darwin, NT. 6. Women's and Children's Hospital, Adelaide, SA. 7. Telethon Kids Institute, Perth, WA.
Abstract
OBJECTIVES: To compare regional differences in the prevalence of rheumatic heart disease (RHD) detected by echocardiographic screening in high-risk Indigenous Australian children, and to describe the logistical and other practical challenges of RHD screening. DESIGN: Cross-sectional screening survey performed between September 2008 and November 2010. SETTING: Thirty-two remote communities in four regions of northern and central Australia. PARTICIPANTS: 3946 Aboriginal or Torres Strait Islander children aged 5-15 years. INTERVENTION: Portable echocardiography was performed by cardiac sonographers. Echocardiograms were recorded and reported offsite by a pool of cardiologists. MAIN OUTCOME MEASURES: RHD was diagnosed according to 2012 World Heart Federation criteria. RESULTS: The prevalence of definite RHD differed between regions, from 4.7/1000 in Far North Queensland to 15.0/1000 in the Top End of the Northern Territory. The prevalence of definite RHD was greater in the Top End than in other regions (odds ratio, 2.3; 95% CI, 1.2-4.6, P = 0.01). Fifty-three per cent of detected cases of definite RHD were new cases; the prevalence of new cases of definite RHD was 4.6/1000 for the entire sample and 7.0/1000 in the Top End. Evaluation of socioeconomic data suggests that the Top End group was the most disadvantaged in our study population. CONCLUSIONS: The prevalence of definite RHD in remote Indigenous Australian children is significant, with a substantial level of undetected disease. Important differences were noted between regions, with the Top End having the highest prevalence of definite RHD, perhaps explained by socioeconomic factors. Regional differences must be considered when evaluating the potential benefit of widespread echocardiographic screening in Australia.
OBJECTIVES: To compare regional differences in the prevalence of rheumatic heart disease (RHD) detected by echocardiographic screening in high-risk Indigenous Australian children, and to describe the logistical and other practical challenges of RHD screening. DESIGN: Cross-sectional screening survey performed between September 2008 and November 2010. SETTING: Thirty-two remote communities in four regions of northern and central Australia. PARTICIPANTS: 3946 Aboriginal or Torres Strait Islander children aged 5-15 years. INTERVENTION: Portable echocardiography was performed by cardiac sonographers. Echocardiograms were recorded and reported offsite by a pool of cardiologists. MAIN OUTCOME MEASURES: RHD was diagnosed according to 2012 World Heart Federation criteria. RESULTS: The prevalence of definite RHD differed between regions, from 4.7/1000 in Far North Queensland to 15.0/1000 in the Top End of the Northern Territory. The prevalence of definite RHD was greater in the Top End than in other regions (odds ratio, 2.3; 95% CI, 1.2-4.6, P = 0.01). Fifty-three per cent of detected cases of definite RHD were new cases; the prevalence of new cases of definite RHD was 4.6/1000 for the entire sample and 7.0/1000 in the Top End. Evaluation of socioeconomic data suggests that the Top End group was the most disadvantaged in our study population. CONCLUSIONS: The prevalence of definite RHD in remote Indigenous Australian children is significant, with a substantial level of undetected disease. Important differences were noted between regions, with the Top End having the highest prevalence of definite RHD, perhaps explained by socioeconomic factors. Regional differences must be considered when evaluating the potential benefit of widespread echocardiographic screening in Australia.
Authors: Madhu Page-Sharp; Jonathan Coward; Brioni R Moore; Sam Salman; Lewis Marshall; Timothy M E Davis; Kevin T Batty; Laurens Manning Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Bo Remenyi; Jonathan Carapetis; John W Stirling; Beatrice Ferreira; Krishnan Kumar; John Lawrenson; Eloi Marijon; Mariana Mirabel; A O Mocumbi; Cleonice Mota; John Paar; Anita Saxena; Janet Scheel; Satu Viali; I B Vijayalakshmi; Gavin R Wheaton; Liesl Zuhlke; Karishma Sidhu; Eliazar Dimalapang; Thomas L Gentles; Nigel J Wilson Journal: Heart Asia Date: 2019-06-24
Authors: Kathryn Roberts; Jeffrey Cannon; David Atkinson; Alex Brown; Graeme Maguire; Bo Remenyi; Gavin Wheaton; Elizabeth Geelhoed; Jonathan R Carapetis Journal: J Am Heart Assoc Date: 2017-03-02 Impact factor: 5.501
Authors: Robert M Hand; Sam Salman; Nelly Newall; Julie Vine; Madhu Page-Sharp; Asha C Bowen; Katherine Gray; Amy Baker; Joseph Kado; John Joseph; Julie Marsh; James Ramsay; Dianne Sika-Paotonu; Kevin T Batty; Laurens Manning; Jonathan Carapetis Journal: J Antimicrob Chemother Date: 2019-07-01 Impact factor: 5.790
Authors: Jessica Langloh de Dassel; Nick de Klerk; Jonathan Rhys Carapetis; Anna P Ralph Journal: J Am Heart Assoc Date: 2018-12-18 Impact factor: 5.501
Authors: Joshua Reginald Francis; Helen Fairhurst; Gillian Whalley; Alex Kaethner; Anna Ralph; Jennifer Yan; James Cush; Vicki Wade; Andre Monteiro; Bo Remenyi Journal: BMJ Open Date: 2020-05-27 Impact factor: 2.692
Authors: Anna P Ralph; Jessica L de Dassel; Adrienne Kirby; Clancy Read; Alison G Mitchell; Graeme P Maguire; Bart J Currie; Ross S Bailie; Vanessa Johnston; Jonathan R Carapetis Journal: J Am Heart Assoc Date: 2018-07-17 Impact factor: 5.501
Authors: Sean Coffey; Ross Roberts-Thomson; Alex Brown; Jonathan Carapetis; Mao Chen; Maurice Enriquez-Sarano; Liesl Zühlke; Bernard D Prendergast Journal: Nat Rev Cardiol Date: 2021-06-25 Impact factor: 32.419